Table 2.
Gene expression profiling of SH-SY5Y cells following exposure to drugs affecting mood.
| Lithium |
Sodium valproate |
||||||
|---|---|---|---|---|---|---|---|
| Gene | Description | p | Fold change | Gene | Description | p | Fold change |
| FOS | FBJ murine osteosarcoma viral oncogene homolog | 0.012 | −2.57 | DRD3 | Dopamine receptor D3 | 0.001 | −7.98 |
| GAD1 | Glutamate decarboxylase 1 | 0.023 | −3.48 | RGS4 | Regulator of G-protein signaling 4 | 0.007 | −2.08 |
| RGS4 | Regulator of G-protein signaling 4 | 0.063 | −1.51 | JUN | Jun oncogene | 0.008 | 2.49 |
| PER3 | Period circadian clock 3 | 0.067 | −1.38 | RELN | Reelin | 0.012 | −1.78 |
| NRG1 | Neuregulin 1 | 0.068 | −1.43 | PER3 | Period circadian clock 3 | 0.026 | −1.48 |
| NR1D1 | Nuclear receptor subfamily 1, group D, member 1 | 0.069 | −1.48 | PAFAH1B3 | Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa | 0.034 | 1.61 |
| RELN | Reelin | 0.078 | −1.94 | GAD1 | Glutamate decarboxylase 1 | 0.035 | −7.45 |
| ACE | Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 | 0.099 | 1.31 | NRG1 | Neuregulin 1 | 0.044 | −1.34 |
| Hs18s | Human 18S ribosomal RNA | 0.105 | 1.64 | MTHFR | Methylenetetrahydrofolate reductase (NADPH) | 0.083 | 1.53 |
| BDNF | Brain-derived neurotrophic factor | 0.106 | −1.39 | RFX4 | Regulatory factor X, 4 (influences HLA class II expression) | 0.092 | −1.49 |
| Cocaine | Amphetamine | ||||||
| Gene | Description | p | Fold change | Gene | Description | p | Fold change |
| SULT1A1 | Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 | 0.088 | 1.68 | MOBP | Myelin-associated oligodendrocyte basic protein | 0.080 | 2.08 |
| DRD3 | Dopamine receptor D3 | 0.110 | −2.08 | XBP1 | X-box binding protein 1 | 0.093 | 1.34 |
| FOS | FBJ murine osteosarcoma viral oncogene homolog | 0.142 | −1.45 | NR1D1 | Nuclear receptor subfamily 1, group D, member 1 | 0.109 | −1.35 |
| MOBP | Myelin-associated oligodendrocyte basic protein | 0.161 | 1.85 | MAG | Malignancy-associated gene | 0.138 | 2.81 |
| SLC6A2 | Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.176 | −1.28 | PAFAH1B3 | Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa | 0.141 | 1.33 |
| GRIK3 | Glutamate receptor, ionotropic, kainate 3 | 0.194 | −1.67 | FKBP5 | FK506 binding protein 5 | 0.159 | −1.34 |
| TIMELESS | Timeless circadian clock | 0.200 | −1.20 | RELN | Reelin | 0.198 | −1.30 |
| NCAM1 | Neural cell adhesion molecule 1 | 0.206 | −1.20 | BCR | Breakpoint cluster region | 0.207 | 1.22 |
| ND4 | Mitochondrially encoded NADH dehydrogenase 4 | 0.232 | 1.15 | MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | 0.208 | 2.52 |
| NR1D1 | Nuclear receptor subfamily 1, group D, member 1 | 0.233 | −1.28 | GABRA5 | Gamma-aminobutyric acid (GABA) A receptor, alpha 5 | 0.213 | −1.78 |
Top 10 changes in gene expression levels between treated (10 µM amphetamine, 10 µM cocaine, 1 mM lithium and 5 mM sodium valproate) and untreated conditions measured using qPCR arrays (Human Mood Disorder 96 StellARrayTM) and Global Pattern Recognition (GPR) statistical analysis. Fold change values are represented as treated conditions normalised to the drug vehicle. Bold font indicates significant changes in gene expression, p<0.05.